Search Results

You are looking at 81 - 90 of 292 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Letter to the Editor: Clinical Implications of Postoperative Radiotherapy on Patient Survival in Stage IIIA Resected Lung Cancer: More Variables Should Be Considered

Donglai Chen, Xiaofan Wang, Qifeng Ding, and Yongbing Chen

neoadjuvant chemotherapy might be administered to patients with suspected stage IIIA-N2 disease? Second, given that the authors provided the number of positive lymph nodes in the tables, why was the total number of harvested nodes, which possibly affected

Full access

Highlights of the NCCN Oncology Research Program

, over the enrollment period, 120 patients will be eligible, with a goal enrollment of 60 patients. Patients can be enrolled regardless of decision for upfront surgery followed by adjuvant or neoadjuvant chemotherapy. Patients must have access to a

Full access

Locoregional Management of Early-Stage Breast Cancer

Presented by: Meena S. Moran and A. Marilyn Leitch

a pathologic complete response to neoadjuvant chemotherapy. 9 The goal of this study was to determine whether the sentinel node procedure could be safely applied post neoadjuvant chemotherapy in patients with needle biopsy–proven positive nodes

Full access

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Lisa A. Gurski

stage (ie, positive nodes or perivesical tissue involvement) or presence of a positive margin, similar to that for patients who undergo a radical cystectomy. Neoadjuvant Chemotherapy One of the most noteworthy issues in treatment is the optimal

Full access

New Treatment Guidelines for Penile Cancer

Philippe E. Spiess

distant disease) were treated with neoadjuvant chemotherapy (paclitaxel, ifosfamide, and cisplatin) and then surgical resection. They reported an objective response rate of 50%. “On the whole, this is far superior to what we see traditionally with surgery

Full access

The Role of Radiation Treatment in the Contemporary Management of Bone Tumors

Borislav Hristov, Ori Shokek, and Deborah A. Frassica

-Yanguas M . A study of the response of osteogenic sarcoma and adjacent normal tissues to radiation . Int J Radiat Oncol Biol Phys 1981 ; 7 : 593 – 595 . 25. DeLaney TF Spiro IJ Suit HD . Neoadjuvant chemotherapy and radiotherapy for large

Full access

Bladder Cancer

James E. Montie, Peter E. Clark, Mario A. Eisenberger, Rizk El-Galley, Richard E. Greenberg, Harry W. Herr, Gary R. Hudes, Deborah A. Kuban, Timothy M. Kuzel, Paul H. Lange, Subodh M. Lele, Jeffrey Michalski, Anthony Patterson, Kamal S. Pohar, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Donald L. Trump, Phillip J. Walther, and Timothy G. Wilson

: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enchanced imaging, and late gadolinium-enhancing imaging . Radiology 1994 ; 193 : 239 – 245 . 25 Grossman HB Natale RB Tangen CM . Neoadjuvant chemotherapy

Full access

Rectal Cancer, Version 2.2015

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Axel Grothey, Howard S. Hochster, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Lucille A. Leong, Edward Lin, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah Freedman-Cass

neoadjuvant chemotherapy preceding chemoRT and resection for stage II/III rectal cancer. 12 – 17 In the Spanish GCR-3 phase II trial, patients were randomized to receive CapeOx either before chemoRT or after surgery. 14 Similar pathologic complete response

Full access

NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

Featured Updates to the NCCN Guidelines

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes

in patients with earlier stage disease. 11 – 13 Trials also suggest that neoadjuvant chemotherapy is beneficial in patients with N2 disease. 14 – 16 Song et al 17 published a meta-analysis of 13 randomized clinical trials evaluating neoadjuvant

Full access

Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study

Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei, and for the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium

declare itself for patients with elevated tumor markers, thereby improving patient selection for surgery. 4 In the current NCCN Guidelines (Version 2.2021), neoadjuvant chemotherapy may be followed by radiotherapy (RT), without clear specification on